What type of study is this?

This is a Animal Study study (also classified as: Quantitative Study).

October 5, 2025Neuro-Oncology

P07.15.a Electroactive Drug Delivery Device for Targeted Intratumoral Therapy

View Full Paper

Ask AI

Bookmark

Authors

JKJoshua KillileaCancer Research UK ALAlbert LeeCancer Research Institute GMGiuseppe MiceliDepartment of Health

Discussion

Member takes

Implication

This device demonstrates improved anti-tumour effects in glioblastoma by facilitating targeted release of drugs, suggesting innovative therapy methods.

Key Points

Active release of doxorubicin in glioblastoma cells significantly improved anti-tumour responses compared to passive controls.
Cytotoxicity data from 3D tumour spheroid models showed enhanced effects of actively released cisplatin over passive release and controls.
Device efficacy was confirmed in an orthotopic mouse model, demonstrating greater diffusion of doxorubicin under active conditions.
The device allows for rapid, localized drug delivery during neuro-surgical procedures, enhancing current cancer treatment approaches.

Cite This Study

Killilea et al. (2025) studied this question.

synapsesocial.com/papers/68e24e6bd6d66a53c2473b41 https://doi.org/10.1093/neuonc/noaf193.261

View Full Paper

Ask AI

Bookmark

Implication

This device demonstrates improved anti-tumour effects in glioblastoma by facilitating targeted release of drugs, suggesting innovative therapy methods.

P07.15.a Electroactive Drug Delivery Device for Targeted Intratumoral Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

P07.15.a Electroactive Drug Delivery Device for Targeted Intratumoral Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider